About
Mucosal Targets
Areas of Focus
Categories
Small Molecule PharmaceuticalNorth & South Carolina
Clinical Trials (11)
View allTotal Trials
11
As Lead Sponsor
9
As Collaborator
2
Total Enrollment
741
By Phase
NA: 1PHASE2: 6PHASE1: 2PHASE1/PHASE2: 2
By Status
COMPLETED: 9TERMINATED: 2
Clinical Trials Pipeline11 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
Today
Hover over trial bars to see details
Recent Trials
NCT03185650Collaborator
Evaluation of Regional Lung Deposition of Inhaled Saline Using the tPAD Device
NACompleted
12 participants
Started: Jul 27, 2017 · Completed: Jul 27, 2018
NCT02871778Lead Sponsor
Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
PHASE2Completed
123 participants
Started: Aug 31, 2016 · Completed: Nov 20, 2018
NCT02824913Lead Sponsor
Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
PHASE2Terminated
1 participants
Started: Jul 31, 2016 · Completed: Mar 31, 2017
NCT02831387Lead Sponsor
Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
PHASE2Terminated
47 participants
Started: Jul 31, 2016 · Completed: Jun 30, 2017
NCT02709109Lead Sponsor
A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
PHASE2Completed
147 participants
Started: Feb 29, 2016 · Completed: Sep 30, 2017
Locations (1)
Headquarters
Durham, NC, United States
Map
Loading map...